These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Effect of Genetic Polymorphisms of Human SLC22A3 in the 5'-flanking Region on OCT3 Expression and Sebum Levels in Human Skin. Takechi T; Hirota T; Fujii K; Nakahara T; Sakai T; Maeda N; Furue M; Ieiri I J Dermatol Sci; 2021 Jan; 101(1):4-13. PubMed ID: 33168399 [TBL] [Abstract][Full Text] [Related]
3. OCT3 promoter haplotype is associated with metformin pharmacokinetics in Koreans. Kwon EY; Chung JY; Park HJ; Kim BM; Kim M; Choi JH Sci Rep; 2018 Nov; 8(1):16965. PubMed ID: 30446679 [TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of novel polymorphisms in the basal promoter of the human transporter, MATE1. Ha Choi J; Wah Yee S; Kim MJ; Nguyen L; Ho Lee J; Kang JO; Hesselson S; Castro RA; Stryke D; Johns SJ; Kwok PY; Ferrin TE; Goo Lee M; Black BL; Ahituv N; Giacomini KM Pharmacogenet Genomics; 2009 Oct; 19(10):770-80. PubMed ID: 19745787 [TBL] [Abstract][Full Text] [Related]
5. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Nies AT; Koepsell H; Winter S; Burk O; Klein K; Kerb R; Zanger UM; Keppler D; Schwab M; Schaeffeler E Hepatology; 2009 Oct; 50(4):1227-40. PubMed ID: 19591196 [TBL] [Abstract][Full Text] [Related]
6. Functional genetic variation in the basal promoter of the organic cation/carnitine transporters OCTN1 (SLC22A4) and OCTN2 (SLC22A5). Tahara H; Yee SW; Urban TJ; Hesselson S; Castro RA; Kawamoto M; Stryke D; Johns SJ; Ferrin TE; Kwok PY; Giacomini KM J Pharmacol Exp Ther; 2009 Apr; 329(1):262-71. PubMed ID: 19141711 [TBL] [Abstract][Full Text] [Related]
8. Diabetes medication associates with DNA methylation of metformin transporter genes in the human liver. García-Calzón S; Perfilyev A; Männistö V; de Mello VD; Nilsson E; Pihlajamäki J; Ling C Clin Epigenetics; 2017; 9():102. PubMed ID: 28947922 [TBL] [Abstract][Full Text] [Related]
9. Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin. Chen L; Pawlikowski B; Schlessinger A; More SS; Stryke D; Johns SJ; Portman MA; Chen E; Ferrin TE; Sali A; Giacomini KM Pharmacogenet Genomics; 2010 Nov; 20(11):687-99. PubMed ID: 20859243 [TBL] [Abstract][Full Text] [Related]
10. Functional analysis of human organic cation transporter OCT3 (SLC22A3) polymorphisms. Sakata T; Anzai N; Kimura T; Miura D; Fukutomi T; Takeda M; Sakurai H; Endou H J Pharmacol Sci; 2010; 113(3):263-6. PubMed ID: 20562519 [TBL] [Abstract][Full Text] [Related]
11. Epigenetic alterations of a novel antioxidant gene Xiong JX; Wang YS; Sheng J; Xiang D; Huang TX; Tan BB; Zeng CM; Li HH; Yang J; Meltzer SJ; Mori Y; Qin YR; Guan XY; Fu L Int J Biol Sci; 2018; 14(12):1658-1668. PubMed ID: 30416380 [TBL] [Abstract][Full Text] [Related]
12. Association between gene polymorphisms of SLC22A3 and methamphetamine use disorder. Aoyama N; Takahashi N; Kitaichi K; Ishihara R; Saito S; Maeno N; Ji X; Takagi K; Sekine Y; Iyo M; Harano M; Komiyama T; Yamada M; Sora I; Ujike H; Iwata N; Inada T; Ozaki N Alcohol Clin Exp Res; 2006 Oct; 30(10):1644-9. PubMed ID: 17010131 [TBL] [Abstract][Full Text] [Related]
13. Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance. Heise M; Lautem A; Knapstein J; Schattenberg JM; Hoppe-Lotichius M; Foltys D; Weiler N; Zimmermann A; Schad A; Gründemann D; Otto G; Galle PR; Schuchmann M; Zimmermann T BMC Cancer; 2012 Mar; 12():109. PubMed ID: 22439694 [TBL] [Abstract][Full Text] [Related]
14. Hypoexpression and epigenetic regulation of candidate tumor suppressor gene CADM-2 in human prostate cancer. Chang G; Xu S; Dhir R; Chandran U; O'Keefe DS; Greenberg NM; Gingrich JR Clin Cancer Res; 2010 Nov; 16(22):5390-401. PubMed ID: 21062931 [TBL] [Abstract][Full Text] [Related]
16. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer. Ogishima T; Shiina H; Breault JE; Tabatabai L; Bassett WW; Enokida H; Li LC; Kawakami T; Urakami S; Ribeiro-Filho LA; Terashima M; Fujime M; Igawa M; Dahiya R Clin Cancer Res; 2005 Feb; 11(3):1028-36. PubMed ID: 15709168 [TBL] [Abstract][Full Text] [Related]
17. Targeted disruption of organic cation transporter 3 attenuates the pharmacologic response to metformin. Chen EC; Liang X; Yee SW; Geier EG; Stocker SL; Chen L; Giacomini KM Mol Pharmacol; 2015 Jul; 88(1):75-83. PubMed ID: 25920679 [TBL] [Abstract][Full Text] [Related]
18. EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling. Kim YJ; Yoon HY; Kim SK; Kim YW; Kim EJ; Kim IY; Kim WJ Clin Cancer Res; 2011 Jul; 17(13):4523-30. PubMed ID: 21571867 [TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of proximal promoter polymorphisms in the human concentrative nucleoside transporter 2 (SLC28A2). Yee SW; Shima JE; Hesselson S; Nguyen L; De Val S; Lafond RJ; Kawamoto M; Johns SJ; Stryke D; Kwok PY; Ferrin TE; Black BL; Gurwitz D; Ahituv N; Giacomini KM J Pharmacol Exp Ther; 2009 Mar; 328(3):699-707. PubMed ID: 19098160 [TBL] [Abstract][Full Text] [Related]
20. Organic Cation Transporter 2 (OCT2/SLC22A2) Gene Variation in the South African Bantu-Speaking Population and Functional Promoter Variants. Wilson NC; Choudhury A; Carstens N; Mavri-Damelin D OMICS; 2017 Mar; 21(3):169-176. PubMed ID: 28253084 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]